Issues related to reimbursement under Medicare Part B
Issues related to Medicare Part D, generally
Issues related to the 340B Drug Pricing Program
Issues related to drug pricing and value, generally
Issues related to pharmacy benefit managers and drug rebate reform
Issues related to drug patents and patent reporting requirements
Reauthorization of the Pandemic All-Hazards Preparedness Act
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to the Inflation Reduction Act (Pub. L. 117-169)
Duration: January 1, 2016
to
present
General Issues: Medicare/Medicaid , Health Issues , Budget/Appropriations , Taxation/Internal Revenue Code , Animals , Fuel/Gas/Oil , Pharmacy
Spending: about $2,260,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2016: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Steven Irizarry Counsel, Senate HELP;
Counsel, Senator Chuck Hagel;
Counsel, House Energy & Commerce Committee;
Counsel, Senate Special Committee on Aging
Israel "Izzy" Klein Deputy Staff Director, Joint Economic Committee, Chairman Chuck Schumer;
Senior Communications Advisor, Representative Ed Markey;
Communications Director, Senator Chuck Schumer;
Press Secretary and Legislative Assistant, Representative Ed Markey
Drew Cole Intern for Senator Don Nickels (R-OK)
Lydia Strunk Deputy Floor Director Speaker Ryan (2015-17); Deputy Floor Director Speaker Boehner (2013-15); House Rules Committee 2011-13; House Republican Cloakroom Floor Assistant 2008-2011 (Minority Leader Boehner/Speaker Boehner)
Vincent A. Roberti n/a
Vincent Roberti Sr. n/a
Israel Klein n/a
Vincent Roberti Sr n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $80,000. The report was filed on April 21.
Original Filing: 301569331.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B
Issues related to Medicare Part D, generally
Issues related to the 340B Drug Pricing Program
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing and value, generally
Issues related to pharmacy benefit managers and drug rebate reform
Issues related to drug patents and patent reporting requirements
Reauthorization of the Pandemic All-Hazards Preparedness Act
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to the Inflation Reduction Act (Pub. L. 117-169)
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $80,000. The report was filed on Jan. 21.
Original Filing: 301534962.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B
Issues related to Medicare Part D, generally
Issues related to the 340B Drug Pricing Program
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing and value, generally
Issues related to pharmacy benefit managers and drug rebate reform
Issues related to drug patents and patent reporting requirements
Reauthorization of the Pandemic All-Hazards Preparedness Act
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to the Inflation Reduction Act (Pub. L. 117-169)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $80,000. The report was filed on Oct. 18, 2023.
Original Filing: 301505054.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B
Issues related to Medicare Part D, generally
Issues related to the 340B Drug Pricing Program
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing and value, generally
Issues related to pharmacy benefit managers and drug rebate reform
Issues related to drug patents and patent reporting requirements
Reauthorization of the Pandemic All-Hazards Preparedness Act
Issues related to the Inflation Reduction Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $80,000. The report was filed on July 18, 2023.
Original Filing: 301478897.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B
Issues related to Medicare Part D, generally
Issues related to the 340B Drug Pricing Program
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing and value, generally
Issues related to pharmacy benefit managers and drug rebate reform
Issues related to drug patents and patent reporting requirements
Reauthorization of the Pandemic All-Hazards Preparedness Act
Issues related to International Pricing Index; Most Favored Nation drug pricing
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $80,000. The report was filed on April 20, 2023.
Original Filing: 301461712.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B
Issues related to Medicare Part D, generally
Issues related to the 340B Drug Pricing Program
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing and value, generally
Issues related to drug patents and patent reporting requirements
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $80,000. The report was filed on Jan. 18, 2023.
Original Filing: 301430300.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B
Issues related to Medicare Part D, generally
Issues related to the 340B Drug Pricing Program
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing and value, generally
Issues related to drug patents and patent reporting requirements
Issues related to International Pricing Index; Most Favored Nation drug pricing
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $80,000. The report was filed on Oct. 20, 2022.
Original Filing: 301415698.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B
Issues related to Medicare Part D, generally
Issues related to Medicaid
Value-based contracting and communications
Issued relating to the 340B Drug Pricing Program
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars, generally
Issues related to drug pricing and value, generally
Issues related to the importation of prescription medicines, generally
Issues related to drug patents and patent reporting requirements
Issues related to International Pricing Index; Most Favored Nation drug pricing
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $80,000. The report was filed on July 19, 2022.
Original Filing: 301387248.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B
Issues related to Medicare Part D, generally
Issues related to Medicaid
Value-based contracting and communications
Issued relating to the 340B Drug Pricing Program
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars, generally
Issues related to drug pricing and value, generally
Issues related to the importation of prescription medicines, generally
Issues related to drug patents and patent reporting requirements
Issues related to International Pricing Index; Most Favored Nation drug pricing
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $80,000. The report was filed on April 17, 2022.
Original Filing: 301357926.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B
Issues related to Medicare Part D, generally
Issues related to Medicaid
Value-based contracting and communications
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issued relating to the 340B Drug Pricing Program
Biodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program
Issues related to biosimilars, generally
Issues related to drug pricing and value, generally
Issues related to the importation of prescription medicines, generally
Issues related to drug patents and patent reporting requirements
Issues related to International Pricing Index; Most Favored Nation drug pricing
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $80,000. The report was filed on Jan. 20, 2022.
Original Filing: 301331587.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B
Issues related to Medicare Part D, generally
Issues related to Medicaid
Value-based contracting and communications
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issued relating to the 340B Drug Pricing Program
Biodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program
Issues related to biosimilars, generally
Issues related to drug pricing and value, generally
Issues related to the importation of prescription medicines, generally
Issues related to drug patents and patent reporting requirements
Issues related to International Pricing Index; Most Favored Nation drug pricing
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $80,000. The report was filed on Oct. 20, 2021.
Original Filing: 301307702.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B
Issues related to Medicare Part D, generally
Issues related to Medicaid
Value-based contracting and communications
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issued relating to the 340B Drug Pricing Program
Biodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program
Issues related to biosimilars, generally
Issues related to drug pricing and value, generally
Issues related to the importation of prescription medicines, generally
Issues related to drug patents and patent reporting requirements
Issues related to International Pricing Index; Most Favored Nation drug pricing
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $80,000. The report was filed on July 20, 2021.
Original Filing: 301287095.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B
Issues related to Medicare Part D, generally
Issues related to Medicaid
Value-based contracting and communications
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issued relating to the 340B Drug Pricing Program
Biodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program
Issues related to biosimilars, generally
Issues related to drug pricing and value, generally
Issues related to the importation of prescription medicines, generally
Issues related to drug patents and patent reporting requirements
Issues related to International Pricing Index; Most Favored Nation drug pricing
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $80,000. The report was filed on April 19, 2021.
Original Filing: 301258257.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B
Issues related to Medicare Part D, generally
Issues related to Medicaid
Value-based contracting and communications
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issued relating to the 340B Drug Pricing Program
Biodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program
Issues related to biosimilars, generally
Issues related to drug pricing and value, generally
Issues related to the importation of prescription medicines, generally
Issues related to drug patents and patent reporting requirements
Issues related to International Pricing Index; Most Favored Nation drug pricing
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $80,000. The report was filed on Jan. 20, 2021.
Original Filing: 301239419.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B generally
Issues related to Medicare Part D, generally
Value-based contracting and communications
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issued relating to the 340B Drug Pricing Program
Biodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program
Issues related to biosimilars, generally
Issues related to drug pricing and value, generally
Issues related to the importation of prescription medicines, generally
Issues related to drug patents and patent reporting requirements
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for antimicrobial resistance programs
Funding for renewable chemicals/bio-based products
Agencies Lobbied
U.S. Senate
Lobbying Issues
Vaccines and infectious diseases; antimicrobials
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2020
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $80,000. The report was filed on Oct. 19, 2020.
Original Filing: 301214496.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B generally
Issues related to Medicare Part D, generally
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Value-based contracting and communications
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the Coronavirus Aid, Relief, and Economic Security (CARES) Act's SBA Paycheck Protection Program
Issued relating to the 340B Drug Pricing Program
Biodefense research, development, and procurement issues; Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program
Issues related to biosimilars, generally; access to samples for testing; coding; naming; interchangeability and pharmacy substitution; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act
Issues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Issues related to the importation of prescription medicines, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for antimicrobial resistance programs
Funding for renewable chemicals/bio-based products
Agencies Lobbied
U.S. Senate
Lobbying Issues
Vaccines and infectious diseases; antimicrobials
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2020
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $80,000. The report was filed on July 20, 2020.
Original Filing: 301201240.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B generally
Issues related to Medicare Part D, generally
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Value-based contracting and communications
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the Coronavirus Aid, Relief, and Economic Security (CARES) Act's SBA Paycheck Protection Program
Issued relating to the 340B Drug Pricing Program
Biodefense research, development, and procurement issues; Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program
Issues related to biosimilars, generally; access to samples for testing; coding; naming; interchangeability and pharmacy substitution; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act
Issues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Issues related to the importation of prescription medicines, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for antimicrobial resistance programs
Funding for renewable chemicals/bio-based products
Agencies Lobbied
U.S. Senate
Lobbying Issues
Vaccines and infectious diseases; antimicrobials
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2020
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $80,000. The report was filed on April 20, 2020.
Original Filing: 301175498.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B generally
Issues related to Medicare Part D, generally
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Value-based contracting and communications
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the Coronavirus Aid, Relief, and Economic Security (CARES) Act's SBA Paycheck Protection Program
Issued relating to the 340B Drug Pricing Program
Biodefense research, development, and procurement issues; Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program
Issues related to biosimilars, generally; access to samples for testing; coding; naming; interchangeability and pharmacy substitution; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act
Issues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Issues related to the importation of prescription medicines, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Genetically engineered (GE) animals
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for antimicrobial resistance programs
Funding for renewable chemicals/bio-based products
Funding for biodefense and emergency preparedness research, development and procurement, including reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Vaccines and infectious diseases; antimicrobials
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biofuels, renewable chemicals/bio-based products
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
Roberti Global (fka Roberti White, LLC) amended a lobbying report for representation of Biotechnology Innovation Organization (BIO) in Q42019 on Jan. 22, 2020.
Original Filing: 301129793.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B generally
Issues related to Medicare Part D, generally
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Value-based contracting and communications
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issued relating to the 340B Drug Pricing Program
Biodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program
Issues related to biosimilars, generally; access to samples for testing; coding; naming; interchangeability and pharmacy substitution; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act
Issues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Issues related to the importation of prescription medicines, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Genetically engineered (GE) animals
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for antimicrobial resistance programs
Funding for renewable chemicals/bio-based products
Funding for biodefense and emergency preparedness research, development and procurement, including reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Vaccines and infectious diseases; antimicrobials
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biofuels, renewable chemicals/bio-based products
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on Jan. 21, 2020.
Original Filing: 301124786.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B generally
Issues related to Medicare Part D, generally
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Value-based contracting and communications
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issued relating to the 340B Drug Pricing Program
Biodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program
Issues related to biosimilars, generally; access to samples for testing; coding; naming; interchangeability and pharmacy substitution; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act
Issues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Issues related to the importation of prescription medicines, generally
Issues related to drug patents and patent reporting requirements
Agencies Lobbied
U.S. Senate
Lobbying Issues
Genetically engineered (GE) animals
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for antimicrobial resistance programs
Funding for renewable chemicals/bio-based products
Funding for biodefense and emergency preparedness research, development and procurement, including reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Vaccines and infectious diseases; antimicrobials
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biofuels, renewable chemicals/bio-based products
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
Roberti Global (fka Roberti White, LLC) amended a lobbying report for representation of Biotechnology Innovation Organization (BIO) in Q32019 on Jan. 22, 2020.
Original Filing: 301129802.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B generally
Issues related to Medicare Part D, generally
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Value-based contracting and communications
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issued relating to the 340B Drug Pricing Program
Biodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program
Issues related to biosimilars, generally; access to samples for testing; coding; naming; interchangeability and pharmacy substitution; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act
Issues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Issues related to the importation of prescription medicines, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Genetically engineered (GE) animals
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for antimicrobial resistance programs
Funding for renewable chemicals/bio-based products
Funding for biodefense and emergency preparedness research, development and procurement, including reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Vaccines and infectious diseases; antimicrobials
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biofuels, renewable chemicals/bio-based products
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on Oct. 21, 2019.
Original Filing: 301078245.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B generally
Issues related to Medicare Part D, generally
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Value-based contracting and communications
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issued relating to the 340B Drug Pricing Program
Biodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program
Issues related to biosimilars, generally; access to samples for testing; coding; naming; interchangeability and pharmacy substitution; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act
Issues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Issues related to the importation of prescription medicines, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Genetically engineered (GE) animals
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for antimicrobial resistance programs
Funding for renewable chemicals/bio-based products
Funding for biodefense and emergency preparedness research, development and procurement, including reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Vaccines and infectious diseases; antimicrobials
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biofuels, renewable chemicals/bio-based products
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on July 22, 2019.
Original Filing: 301056203.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B generally
Issues related to Medicare Part D, generally
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Value-based contracting and communications
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issued relating to the 340B Drug Pricing Program
Biodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program
Issues related to biosimilars, generally; access to samples for testing; coding; naming; interchangeability and pharmacy substitution; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act
Issues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Issues related to the importation of prescription medicines, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Genetically engineered (GE) animals
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for antimicrobial resistance programs
Funding for renewable chemicals/bio-based products
Funding for biodefense and emergency preparedness research, development and procurement, including reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Vaccines and infectious diseases; antimicrobials
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biofuels, renewable chemicals/bio-based products
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on April 22, 2019.
Original Filing: 301038672.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B generally
Issues related to Medicare Part D, generally
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Value-based contracting and communications
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issued relating to the 340B Drug Pricing Program
Biodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program
Issues related to biosimilars, generally; access to samples for testing; coding; naming; interchangeability and pharmacy substitution; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act
Issues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Issues related to the importation of prescription medicines, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Genetically engineered (GE) animals
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for antimicrobial resistance programs
Funding for renewable chemicals/bio-based products
Funding for biodefense and emergency preparedness research, development and procurement, including reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Vaccines and infectious diseases; antimicrobials
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biofuels, renewable chemicals/bio-based products
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on Jan. 22, 2019.
Original Filing: 301015962.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B generally
Issues related to Medicare Part D, generally
Medicaid; drug benefit design; pricing and rebates; and Section 1115 waivers
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issued relating to the 340B Drug Pricing Program, including the 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act (H.R. 4710); the Helping Ensure Low-income Patients have Access to Care and Treatment (HELP) Act (S. 2312); and the Ensuring the Value of the 340B Program Act (S. 2453).
Biodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program
Issues related to biosimilars, generally; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212)
Issues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469); and the Improving Access to Affordable Prescription Drugs Act (H.R. 1776/S. 771)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Genetically engineered (GE) animals
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for Antimicrobial Resistance Programs
Funding for biofuels; Farm Bill Reauthorization
Funding for Biodefense and Emergency Preparedness Research, Development and Procurement, including reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA) (S. 2852/H.R. 6378)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Vaccines and infectious diseases; antimicrobials
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biofuels, renewable chemicals/bio-based products
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on Oct. 22, 2018.
Original Filing: 300997803.xml
Lobbying Issues
Issues related to reimbursement under Medicare Part B generally
Issues related to Medicare Part D, generally
Medicaid; drug benefit design; pricing and rebates; and Section 1115 waivers
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issued relating to the 340B Drug Pricing Program, including the 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act (H.R. 4710); the Helping Ensure Low-income Patients have Access to Care and Treatment (HELP) Act (S. 2312); and the Ensuring the Value of the 340B Program Act (S. 2453).
Biodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program
Issues related to biosimilars, generally; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212)
Issues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469); and the Improving Access to Affordable Prescription Drugs Act (H.R. 1776/S. 771)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Genetically engineered (GE) animals
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for Antimicrobial Resistance Programs
Funding for biofuels; Farm Bill Reauthorization
Funding for Biodefense and Emergency Preparedness Research, Development and Procurement, including reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA) (S. 2852/H.R. 6378)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Vaccines and infectious diseases; antimicrobials
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2018
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on July 20, 2018.
Original Filing: 300977123.xml
Lobbying Issues
- Issues related to reimbursement under Medicare Part B generally; Bipartisan Budget Act (H.R. 1892); Consolidated Appropriations Act (H.R. 1625)
- Issues related to Medicare Part D, generally; Bipartisan Budget Act (H.R. 1892); Consolidated Appropriations Act (H.R. 1625)
- Medicaid; drug benefit design; pricing and rebates; and Section 1115 waivers
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issued relating to the 340B Drug Pricing Program, including the 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act (H.R. 4710); the Helping Ensure Low-income Patients have Access to Care and Treatment (HELP) Act (S. 2312); and the Ensuring the Value of the 340B Program Act (S. 2453)
- Biodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program
- Issues related to biosimilars, generally; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212)
- Drug evaluation and review; compassionate use expanded access; Right to Try Act of 2017 (H.R. 878/S. 204); expedited pathways; innovation incentives; implementation of PDUFA IV and BSUFA II
- Issues related to drug pricing and value, generally; Improving Access to Affordable Prescription Drug Act (S. 771)
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
- Vaccines and infectious diseases; antimicrobials
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act of 2018; amendment on GE Salmon Labeling
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Funding for Antimicrobial Resistance Programs
- Funding for biofuels; Farm Bill Reauthorization
- Funding for Biodefense and Emergency Preparedness Research, Development and Procurement, including reauthorization of the Pandemic All-Hazards Preparedness Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Biofuels, renewable chemicals/bio-based products
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2018
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on April 20, 2018.
Original Filing: 300957032.xml
Lobbying Issues
- Issues related to reimbursement under Medicare Part B generally; Bipartisan Budget Act (H.R. 1892); Consolidated Appropriations Act (H.R. 1625)
- Issues related to Medicare Part D, generally; Bipartisan Budget Act (H.R. 1892); Consolidated Appropriations Act (H.R. 1625)
- Medicaid; drug benefit design; pricing and rebates; and Section 1115 waivers
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issued relating to the 340B Drug Pricing Program, including the 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act (H.R. 4710); the Helping Ensure Low-income Patients have Access to Care and Treatment (HELP) Act (S. 2312); and the Ensuring the Value of the 340B Program Act (S. 2453)
- Biodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program
- Issues related to biosimilars, generally; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212)
- Drug evaluation and review; compassionate use expanded access; Right to Try Act of 2017 (H.R. 878/S. 204); expedited pathways; innovation incentives; implementation of PDUFA IV and BSUFA II
- Issues related to drug pricing and value, generally; Improving Access to Affordable Prescription Drug Act (S. 771)
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
- Vaccines and infectious diseases; antimicrobials
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Biofuels, renewable chemicals/bio-based products
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
- Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act of 2018; amendment on GE Salmon Labeling
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on Jan. 22, 2018.
Original Filing: 300933099.xml
Lobbying Issues
- Issues involving reimbursement for biological products under the Medicare and Medicaid programs
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Legislation repealing and replacing the Affordable Care Act, including the American Health Care Act (H.R. 1628)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues relating to the 340B Drug Pricing Program
- Issues related to biosimilars, generally
- Issues related to drug pricing, including the Improving Access to Affordable Prescription Drug Act (S. 771)
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
- Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA)
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on Oct. 20, 2017.
Original Filing: 300914471.xml
Lobbying Issues
- Issues involving reimbursement for biological products under the Medicare and Medicaid programs
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Legislation repealing and replacing the Affordable Care Act, including the American Health Care Act (H.R. 1628)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues relating to the 340B Drug Pricing Program
- FDA Reauthorization Act (H.R. 2430/S. 934)
- Issues related to biosimilars, generally
- Issues related to drug pricing, including the Improving Access to Affordable Prescription Drug Act (S. 771)
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on July 20, 2017.
Original Filing: 300894193.xml
Lobbying Issues
- Issues involving reimbursement for biological products under the Medicare and Medicaid programs
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Legislation repealing and replacing the Affordable Care Act, including the American Health Care Act (H.R. 1628)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues relating to the 340B Drug Pricing Program
- FDA Reauthorization Act (H.R. 2430/S. 934)
- Issues related to biosimilars, generally
- Issues related to drug pricing, including the Improving Access to Affordable Prescription Drug Act (S. 771)
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on April 20, 2017.
Original Filing: 300876579.xml
Lobbying Issues
- Issues involving reimbursement for biological products under the Medicare and Medicaid programs
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Legislation repealing and replacing the Affordable Care Act, including the American Health Care Act (H.R. 1628)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues relating to the 340B Drug Pricing Program
- Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), including reauthorization of the Prescription Drug User Fee Act (PDUFA VI)
- Issues related to biosimilars, generally
- Issues related to drug pricing, including the Improving Access to Affordable Prescription Drug Act (S. 771)
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $60,000. The report was filed on Jan. 23, 2017.
Original Filing: 300856240.xml
Lobbying Issues
- Issues involving reimbursement for biological products under the Medicare and Medicaid programs
- CMS Proposed Part B Drug payment demonstration rule
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues involving the Federal, Food, Drug, and Cosmetic Act, including, but not limited to, legislation and regulations affecting drugs and biologics
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Innovation for Healthier Americans (Senate)
- 21st Century Cures Act (H.R. 6)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $40,000. The report was filed on Oct. 20, 2016.
Original Filing: 300837716.xml
Lobbying Issues
- Issues involving reimbursement for biological products under the Medicare and Medicaid programs
- CMS Proposed Part B Drug payment demonstration rule
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues involving the Federal, Food, Drug, and Cosmetic Act, including, but not limited to, legislation and regulations affecting drugs and biologics.
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Innovation for Healthier Americans (Senate)
- 21st Century Cures Act (H.R. 6)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $40,000. The report was filed on July 20, 2016.
Original Filing: 300820275.xml
Lobbying Issues
- Issues involving reimbursement for biological products under the Medicare and Medicaid programs
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues involving the Federal, Food, Drug and Cosmetic Act, including, but not limited to, legislation and regulations affecting drugs and biologics.
- CMS proposed Part B Drug payment demonstration rule
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Biotechnology Innovation Organization (BIO) , earning $40,000. The report was filed on April 20, 2016.
Original Filing: 300803135.xml
Lobbying Issues
- Issues involving reimbursement for biological products under the Medicare and Medicaid programs
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues involving the Federal, Food, Drug and Cosmetic Act, including, but not limited to, legislation and regulations affecting drugs and biologics.
- CMS proposed Part B Drug payment demonstration rule
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
Roberti Global (fka Roberti White, LLC) filed a lobbying registration on Feb. 4, 2016 to represent Biotechnology Innovation Organization (BIO), effective Jan. 1, 2016.
Original Filing: 300786082.xml
Issue(s) they said they’d lobby about: - HCR - Issues involving the Federal, Food, Drug and Cosmetic Act, including, but not limited to, legislation and regulations affecting drugs and biologics.
- MMM - Issues involving reimbursement for biological products under the Medicare and Medicaid programs. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...